masitinib   Click here for help

GtoPdb Ligand ID: 5656

Synonyms: AB-1010 | AB1010 | Masican® (proposed trade name)
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Using the trade name Masivet, this compound has been used for several years to treat mast cell tumours in dogs [6]. It is a receptor tyrosine kinase (RTK) inhibitor, with inhibitory activity at the cKIT, platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) RTKs [4].

SARS-CoV-2: Using X-ray crystallography, masitinib has been shown to bind (non-covalently) into the catalytic site of the SARS-CoV-2 3CL protease (Mpro) [3], which corresponds with detection of in vitro Mpro inhibitory activity. It does not bind to the other viral protease PLpro.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 101.63
Molecular weight 498.22
XLogP 3.41
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1scc(n1)c1cccnc1)C
Isomeric SMILES CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1scc(n1)c1cccnc1)C
InChI InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
InChI Key WJEOLQLKVOPQFV-UHFFFAOYSA-N
Immunopharmacology Comments
Masitinib has completed Phase 3 clinical trials for asthma and rheumatoid arthritis, but the outcomes from these trials have not been published. Results from Phase 2 NCT00842270 in asthma [7], and Phase 2a NCT00831922 in rheumatoid arthritis [8], were reported in 2009 .
Immunopharmacology Disease
Disease X-Refs Comment References
Mastocytosis Disease Ontology: DOID:350
EMA orphan drug for mastocytosis.